4/17/2026

Ifosfamide Injection

Products Affected - Description

- IFEX powder for solution for injection, Baxter, 1 gram, vial, 1 count, NDC 00338-3991-01
- IFEX powder for solution for injection, Baxter, 3 gram, vial, 1 count, NDC 00338-3993-01
- Ifosfamide powder for solution for injection, Baxter, 1 gram, vial, 1 count, NDC 10019-0925-01
- Ifosfamide powder for solution for injection, Baxter, 3 gram, vial, 1 count, NDC 10019-0926-02
- Ifosfamide lyophilized powder for injection, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0142-10

Reason for the Shortage

- Baxter has ifosfamide on shortage due to increased demand.
- Fresenius Kabi did not provide a reason for the shortage.
- Hikma has ifosfaminde solution for injection available.

Available Products

- Ifosfamide injection, Hikma, 50 mg/mL, 20 mL vial, NDC 00143-9531-01
- Ifosfamide injection, Hikma, 50 mg/mL, 60 mL vial, NDC 00143-9530-01

Estimated Resupply Dates

- Fresenius Kabi has 1 gram vials on back order and the company estimates a release date of late-April 2026.
- Baxter has 1 gram and 3 gram vials on a limited allocation.
- Baxter has IFEX 1 gram vials on a limited allocation. The 3 gram vials are on back order and the company estimates a release date of 3rd quarter 2026.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.